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Adipocytes secrete highly active biological mole­
cules like leptin, resistin and adiponectin [1]. Leptin is 
a 16­kD polypeptide which has a role in nutrient intake 
and in the regulation of metabolism [2]. Some stu­
dies showed a significant association between leptin 
level and blood cell count [2, 3]. Recently, it has been 
demonstrated that leptin receptors were expressed on 
CD34+ hematopoietic stem cells [4] and that leptin had 
influence on the maturation and proliferation of normal 
hematopoietic cells [5, 6]. In addition, it was stated 
that leukemic cells in newly diagnosed acute or chronic 
leukemia patients expressed leptin receptors [2, 4]. It 
was suggested that leptin receptor expression occurred 
mainly on immature leukemic cells; and that leptin had 
a role in leukomogenesis [2].
Another protein of adipocyte origin is resistin which 
was found to be associated with the development of 
obesity and insulin resistance in animals [7]. In hu­
mans, resistin is mainly expressed on inflammatory 
cells; and proinflammatory cytokines increase the 
expression of resistin on monocytes [8]. Resistin was 
shown role in the relation between inflammation and 
insulin resistance [7]. It is known that steroids cause 
resistin expression, thereby increasing insulin resis­
tance [9]. Until now, no study on the levels of resistin 
in hematological malignancies has been conducted.
In this study, we evaluated leptin and resistin levels 
in patients with various hematologic malignancies; 
compared these data with that of the healthy control 
group; and determined clinical and laboratory parame­
ters with which they were associated.
MATERIALS AND METHODS
This study was conducted in the Department of 
Hematology, Trakya University Medical Faculty; 21 lym­
phoma, 14 multiple myeloma (MM), 14 acute leukemia, 
and 13 chronic lymhocytic leukemia (CLL) patients were 
included into the study. The control group composed 
of 25 healthy subjects within the same age range. Of 
lymphoma patients, 11 had Hodgkin lymphoma (HL) and 
10 had non­Hodgkin lymphoma (NHL). Of leukemia pa­
tients, 11 had acute nonlymphoblastic leukemia (ANLL) 
and 3 had acute lymphoblastic leukemia (ALL). Patients 
were either initially diagnosed or they were relapsed 
patients. All patients were off treatment for at least 3 
months. Patients with documented infection within the 
last 2 weeks; those with febrile neutropenia, sepsis, any 
organ failure (kidney, liver, lung, heart); patients with 
hypertension or diabetes were excluded.
All CLL patients fulfilled CLL diagnostic criteria defined 
by the International Workshop on CLL [10]. The diagno­
ses of HL and NHL were based on the histopathologic 
examination of a lymph node or extranodal tissue biopsy 
specimen. All CLL patients were classified into stages 
according to the system of Rai et al. [11]. Lymphoma 
patients were staged clinically according to Ann­Arbor 
classification [12]. MM patients were classified according 
to Durie­Salmon staging system [13]. CLL patients with 
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Rai stages III, IV were accepted to have advanced­stage 
disease. Lymphoma patients with Ann­Arbor stages III, 
IV had advanced­stage disease. MM patients with stage 
III disease had advanced stage disease. Seventeen 
lymhoma, 6 CLL and 12 MM patients had advanced 
stage disease. The International Prognostic Index (IPI) 
including age, stage, performance status, extranodal 
involvement, and LDH was calculated in NHL patients. 
The International Prognostic Score (IPS) was calculated 
in advanced­stage HL patients.
Data about patients’ primary hematological dis­
eases, demographic and clinical features were recorded 
down from hospital files. Body mass index (BMI) was 
calculated by dividing body weight (kg) by square height 
(m). Blood samples were obtained after an overnight 
fast when all subjects were still fasting. Whole blood 
count, serum total cholesterol, HDL, LDL, triglyceride, 
erythrocyte sedimentation rate (ESR), C­reactive pro­
tein (CRP) were determined. In addition, flow cytometry 
results in CLL patients were recorded down. Serum 
leptin and resistin (BioVendor Labaratory Medicine, Inc. 
Brno, Czech Republic) were determined by the method 
of enzyme­linked immunosorbent assay (ELISA). The 
minimum detectable value of leptin was 0.5 ng/ml. The 
intraassay coefficient of variation is 4.8 to 7.4%, and the 
interassay coefficient of variation is 4.3 to 8.8%. The 
minimum detectable value of resistin was 0.2 ng/ml. The 
intraassay coefficient of variation is 3.2 to 4%, and the 
interassay coefficient of variation is 6.3 to 7.2%.
One­way variance analysis (ANOVA) was used to 
analyze variances among the groups. Statistically 
significant differences obtained from these analyses 
were further tested by the Tukey test for post hoc pair­
wise comparisons between each group, with p values 
adjusted downward to roughly 0.01. Correlation was 
calculated according to Pearson’s coefficient.
RESULTS
There was no significant difference between the he­
matological malignancy and the control group in age, 
sex, and mean BMI (p > 0.05). The clinical features, 
whole blood counts, and acute phase parameters of 
the groups are seen in Table 1.
Mean leptin levels in MM and CLL patients were signif­
icantly higher than in the control group (p < 0.01). Resistin 
level was significantly higher in lymphoma patients than in 
CLL, acute leukemia and the control group (p < 0.01). In 
both the control group and in patients with hematological 
malignancies, serum leptin levels were higher in females 
than in males; however, the difference was significant in 
only the control group (p = 0.01). Leptin, resistin levels 
and biochemical values are seen in Table 2.
In the control group, leptin level had a signifi­
cant negative correlation with the hemoglobin level 
(r = –0.44, p = 0.047). In patients with hematological 
malignancies, leptin level correlated with BMI (r = 0.32, 
p = 0.02); resistin level, on the other hand, correlated 
with the platelet count (r = 0.26, p = 0.044).
HL and NHL groups were not different in their leptin 
and resistin levels (p>0.05). As most lymhoma patients 
had advanced stage disease, differences among 
stages could not be calculated. In lymphoma patients, 
leptin level correlated with hemoglobin level (r = 0.64, 
p = 0.055); resistin level correlated negatively with HDL 
(r = –0.51, p = 0.04). In addition, it was detected that 
IPS score in HL patients and IPI score in NHL patients 
had negative correlations with leptin level (respectively, 
r = –0.9, p = 0.002 and r = –0.77, p = 0.016).
In CLL group, leptin and resistin levels did not differ 
between early and advanced stage patients (p > 0.05). 
In the CLL group, leptin level had a significant negative 
correlation with triglyceride level (r = –0.71, p = 0.02). In 
addition, the percentage of CD38­positive lymphocytes 
Table 1. The general clinical features, whole blood counts, and acute phase responses of the studied groups of the patients
Lymphoma CLL Acute leukemia Multiple myeloma Controls
n (M/F) 21 (13/8) 13 (9/4) 14 (8/6) 14 (8/6) 25 (15/10)
Age (years) 55.1 ± 15.3 60.2 ± 9.9 49.5 ± 16.2 60.7 ± 9.5 54.5 ± 12
BMI (kg/m2) 24.3 ± 4.1 25.1 ± 3.3 25.8 ± 3.4 26.7 ± 3.8 25.4 ± 3.4
Previous steroid usage, n (%) 13 (61.9) 1 (7.7) 2 (14.3) 11 (78.6) —
Hemoglobin (g/dl) 10.4 ± 2.4 10.7 ± 3.6 8.8 ± 2.4 9.3 ± 2.1 13 ± 1.6a
Leukocytes (109/l) 11.4 ± 16.2 69.5 ± 64.6b 19.2 ± 32.3 5.9 ± 2.9 6.6 ± 1.2
Platelets (109/l) 266 ± 115 168 ± 102 65 ± 64.5c 217 ±  91 245 ± 55
ESR (mm/hr) 53.6 ± 45.1 32.3 ± 40 70.1 ± 47.1 95.2 ± 33.3e 11.9 ± 10.7d
CRP (mg/dl) 3.9 ± 6.5 1.3 ± 1.3 4.1 ± 5.7 1.8 ± 1.5 —
IGT: impaired glucose tolerance; DM: diabetes mellitus.
(a): p ≤ 0.001, controls different from all other groups.
(b): p ≤ 0.001, CLL different from all other groups.
(c): p ≤ 0.001, acute leukemia is different from all other groups.
(d): p ≤ 0.001, controls different from lymphoma, MM and acute leukemia.
(e): p < 0.001, MM different from lymphoma, CLL.
Table 2. Leptin, resistin levels and other laboratory parameters of the groups
Lymphoma CLL Acute leukemia Multiple myeloma Controls
Leptin (ng/ml) 16.4 ± 10.4 19.4 ± 12.4a 13.2 + 10.6 22.6 ± 14.7a 10.3 ± 7.6
Resistin (ng/ml) 3.94 ± 3.4b 1.9 ± 0.8 2.04 ± 1.2 3.3 ± 3.3 1.97 ± 0.6
Glucose (mg/dl) 96.9 ± 10.8 106.9 ± 16.6 106.8 ± 15.2 98.3 ± 20.3 98.2 ± 14.9
Uric acid (mg/dl) 4.5 ± 1.4 4.6 ± 1.5 5.3 ± 3.1 5.6 + 2.4 4.6 ± 1.3
Triglyceride (mg/dl) 103 ± 49.7 121.8 ± 41.2 122.7 ± 54.4 109.4 ± 55.6 127 ± 94
T. Cholesterol (mg/dl) 164.2 ± 44.1 158.4 ± 38 146.9 ± 38 152.2 ± 44 182 ± 32
HDL (mg/dl) 48.6 ± 5.9 41.8 ± 9.2c 51.8 ± 7.5 51 ± 10.3 49.3 ± 6.8
LDL (mg/dl) 90.9 ± 36.2 86 ± 36.1 77.6 ± 33.4 86.9 ± 42.9 107.3 ± 30.6
(a): p < 0.01: CLL and MM different from controls.
(b): p < 0.01: the lymphoma group is different from CLL, acute leukemia and control groups.
(c): p < 0.01: CLL is different from controls, acute leukemia and MM.
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in CLL group had a correlation with leptin level (r = 0.68, 
p = 0.03). In the acute leukemia group, resistin level had 
a negative correlation with BMI (r = –0.59, p = 0.03).
27 of 62 (43.5%) patients with hematological malignan­
cies had used a chemotherapy regimen including steroids. 
The serum leptin level in the patients who used previously 
steroids did not differ significantly from those who did not 
use steroids (p > 0.05). There was a trend towards higher 
resistin levels in patients who used steroids previously 
when compared to patients who did not use steroids; how­
ever, the difference was not significant (3.5 ± 3 vs. 2.5 ± 
2.4 ng/ml, p = 0.06). There was no difference in BMI and 
other laboratory parameters between steroid­users and 
steroid­nonusers among patients (p > 0.05). In each hema­
tological malignancy group, serum leptin and resistin levels 
were not found to differ between patients who previously 
used steroids and or did not use them (p > 0.05).
DISCUSSION
In our study, leptin levels in MM and CLL patients 
were higher than in the control group, and resistin level 
in lymphoma patients was higher than in CLL, acute 
leukemia and control groups. It was reported that leptin 
receptors were expressed on leukemic cells, especially 
on immature ones [2]. In our study, we did not find any 
increase in serum leptin levels in acute leukemia subjects. 
Nevertheless, we detected higher leptin levels in CLL. 
One study reported increased levels of leptin in AML, 
ALL and CML; but, contrary to our results, there was no 
increase in CLL [14]. Another study demonstrated that 
leptin level was lower in untreated AML patients, and that 
it did not vary with chemotherapy or with the development 
of febrile neutropenia [15]. We found no change in leptin 
levels in our acute leukemia patients.
In our study, leptin level had a negative correlation with 
hemoglobin in the control group. Similar to our study, a 
negative correlation between hemoglobin and leptin level 
has been reported in healthy Japanese adults [16]. On 
the contrary, another study found a positive correlation 
between leptin level and both the erythrocyte and leuko­
cyte counts in Japanese adolescents [17]. One study from 
France observed just a weak relationship between leptin 
level and leukocyte count in hospitalized patients [6]. It 
was reported that fat mass in humans was associated with 
leukocyte count and leptin level [3]. As a result, we might 
suggest that leptin might have different relationships with 
hematopoiesis according to differences in age and sex.
It was interesting that in our lymphoma patients, 
contrary to controls, there was a positive correlation 
between leptin and hemoglobin levels. Although it 
was shown that leptin stimulated macrophage and 
granulocyte colonies by itself, and improved erythroid 
development synergistically with eritropoietin [18]; 
there is not sufficient data in literature about the role 
of leptin in erythropoiesis in lymphoma patients.
It was reported that leptin level in adults was associ­
ated with obesity and BMI [17]. In our study, the groups 
did not differ in their BMI; however, leptin level had a 
significant correlation with BMI only in hematologic ma­
lignancy patients, there was no such correlation in the 
control group. We might say that leptin­BMI relationship 
was preserved in hematologic malignancy patients.
Leptin is a fundamental factor for human T cell 
proliferation and it induces T helper type I immune 
reactions [19]. Leptin has also been shown to activate 
CD4+ T cells [19]. Leptin might also be an “acute 
phase protein of fat tissue” which supports the immune 
system during a short­term infectious disease [20]. 
Leptin­deficient mice exhibit impaired host defences 
[21] and starvation with low serum leptin levels leads 
to immunosuppression [22]. Serum levels of leptin are 
increased during some chronic inflammatory diseases 
[20]. Increased leptin levels in our MM and CLL pa­
tients might be associated with increased tendency to 
infections and immune dysfunction in these disorders. 
Nevertheless, more data on this subject are needed.
There is no study on the level of resistin, which is 
related with insulin resistance and shown to increase 
with steroid usage, in hematologic malignancies. In our 
study, we found increased resistin levels in the lymphoma 
group. Recently, it has been demonstrated that resistin 
level was correlated with inflammation markers — in 
addition to insulin resistance — and was predictive of 
atherosclerotic coronary events [7]. In addition, proin­
flammatory cytokines like TNF­α and IL­6 were reported 
to be associated with insulin resistance in adipose tissue 
and increase resistin level [23]. In our study, we could 
not detect any significant association between resistin 
level and any inflammatory parameter (ESR, CRP) in our 
control and hematologic malignancy groups. Neverthe­
less, resistin level correlated with only the platelet count 
in our hematologic malignancy patients.
The increase in leptin and resistin levels in lym­
phoma and MM patients who used corticosteroids 
more intensively and more frequently than others 
points to a role for steroids. Steroid intake affects 
resistin level; in addition, it has been recently reported 
that physiologic­dose steroids increase leptin secre­
tion [9]. However, none of our patients were cur­
rently using steroids. In addition, when we evaluated 
all cases in our study we observed that leptin levels in 
previous steroid­user and ­nonuser groups were not 
different. Although resistin level was higher in previous 
steroid­users, the difference was not significant.
An interesting result of our study was that leptin level 
had negative correlations with parameters of poor prog­
nosis like IPS in HL and IPI in NHL. On the contrary, in CLL 
patients, leptin level had a correlation with the poor prog­
nostic marker CD38 level. As the number of our patients 
was not high, it is difficult to come to a certain conclusion 
about the prognostic importance of leptin level. Further 
studies should be conducted about this subject.
As a result, we found that leptin level was increased 
in CLL and MM; and resistin level was increased in 
lymhoma patients who were not currently using any 
chemotherapeutic agent or steroids. This finding might 
suggest that leptin in CLL and MM, and resistin in lym­
homa might be associated with disease pathogenesis; 
and immune changes and the inflammatory response 
which occur during the courses of these diseases.
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УРОВЕНЬ ЛЕПТИНА И РЕЗИСТИНА В СЫВОРОТКЕ КРОВИ 
БОЛЬНЫХ ОНКОгЕмАТОЛОгИчЕСКИмИ ЗАБОЛЕВАНИямИ: 
КОРРЕЛяЦИя С КЛИНИчЕСКИмИ ХАРАКТЕРИСТИКАмИ
Цель: определить уровни содержания лептина и резистина в сыворотке крови больных с различными онкогематологическими 
заболеваниями. Методы: обследован 21 больной лимфомой, 14 — множественной миеломой (ММ), 14 — острой лейкемией, 
13 — хронической лимфоцитарной лейкемией (ХЛЛ), и 25 здоровых доноров. У пациентов определены такие характеристики: 
индекс массы тела (ИМТ), гематологические параметры, содержание липидов в сыворотке крови. Содержание лептина и ре-
зистина в сыворотке крови определяли иммуноферментным методом. Результаты: уровень лептина в сыворотке крови был 
значительно выше у больных с ХЛЛ и ММ, чем таковой у контрольной группы (р < 0,01). Уровень резистина был значительно 
выше в группе больных с лимфомами по сравнению с ХЛЛ, острой лейкемией и контрольной группами (р < 0,01). В контрольной 
группе уровень лептина отрицательно коррелировал с уровнем гемоглобина (r = –0,44, р = 0,047), а во всех группах больных 
уровень лептина коррелировал с ИМТ (r = 0,32, р = 0,02). Уровень лептина при лимфомах коррелировал с уровнем гемоглобина 
(r = 0,64, р = 0,005), уровень резистина коррелировал с количеством тромбоцитов у больных всех групп (r = 0,26, р = 0,044). При 
лимфоме Ходжкина выявлена отрицательная корреляция между уровнем лептина и величиной международной прогностической 
шкалы (r = -0,9, р = 0,002), при неходжкинской лимфоме — величиной международного прогностического индекса (r = –0,77, 
р = 0,03), у больных ХЛЛ — с уровнем экспрессии CD38 (r = 0,68, р = 0,03). Выводы: у больных ММ и ХЛЛ выявлен высокий 
уровень лептина, а с лимфомами — высокий уровень резистина: этот факт указывает на то, что у больных указанными онкоге-
матологическими заболеваниями могут возникать изменения в структуре жировой ткани и обмене веществ.
Ключевые слова: лептин, резистин, хроническая лимфоцитарная лейкемия, множественная миелома, лимфома.
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